MX2016005808A - Composiciones y metodos para el tratamiento de enfermedades virales con moduladores de pde4. - Google Patents

Composiciones y metodos para el tratamiento de enfermedades virales con moduladores de pde4.

Info

Publication number
MX2016005808A
MX2016005808A MX2016005808A MX2016005808A MX2016005808A MX 2016005808 A MX2016005808 A MX 2016005808A MX 2016005808 A MX2016005808 A MX 2016005808A MX 2016005808 A MX2016005808 A MX 2016005808A MX 2016005808 A MX2016005808 A MX 2016005808A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treatment
viral diseases
pde4 modulators
Prior art date
Application number
MX2016005808A
Other languages
English (en)
Inventor
Jerome B Zeldis
Vikram Khetani
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of MX2016005808A publication Critical patent/MX2016005808A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se describen los métodos de tratamiento y/o prevención de enfermedades y trastornos virales, como aquellos que se mejoran mediante la inhibición de PDE4.
MX2016005808A 2013-11-06 2014-11-05 Composiciones y metodos para el tratamiento de enfermedades virales con moduladores de pde4. MX2016005808A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900489P 2013-11-06 2013-11-06
PCT/US2014/064047 WO2015069711A1 (en) 2013-11-06 2014-11-05 Compositions and methods for the treatment of viral diseases with pde4 modulators

Publications (1)

Publication Number Publication Date
MX2016005808A true MX2016005808A (es) 2016-07-18

Family

ID=51999519

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005808A MX2016005808A (es) 2013-11-06 2014-11-05 Composiciones y metodos para el tratamiento de enfermedades virales con moduladores de pde4.

Country Status (14)

Country Link
US (1) US20160289188A1 (es)
EP (1) EP3065778A1 (es)
JP (1) JP2016540041A (es)
KR (1) KR20160068981A (es)
CN (1) CN105873611A (es)
AR (1) AR099283A1 (es)
AU (1) AU2014346877A1 (es)
CA (1) CA2929539A1 (es)
EA (1) EA201690937A1 (es)
IL (1) IL245511A0 (es)
MX (1) MX2016005808A (es)
PH (1) PH12016500824A1 (es)
SG (1) SG11201603469UA (es)
WO (1) WO2015069711A1 (es)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
AU2003294312A1 (en) * 2002-11-18 2004-07-09 Celgene Corporation Methods of usig and compositions comprising (-)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CN1452982A (zh) * 2003-06-25 2003-11-05 上海兴康医药研究开发有限公司 用于预防sars的利巴韦林黏膜给药制剂及制备方法
MXPA06012279A (es) * 2004-04-23 2007-01-31 Celgene Corp Metodos de uso y composiciones que comprenden moduladores de pde4 para el tratamiento y manejo de la hipertension pulmonar.
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
CA2698075C (en) * 2007-08-27 2016-04-12 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
US20100080807A1 (en) * 2008-09-26 2010-04-01 National Taiwan University Methods and Compositions for Treating Viral Hemorrhagic Fever
US20100297033A1 (en) * 2009-05-21 2010-11-25 Mcleay Matthew T Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease
EP2555769B1 (en) * 2010-04-07 2022-01-12 Amgen (Europe) GmbH Methods for treating respiratory viral infection
WO2012118599A1 (en) * 2011-02-28 2012-09-07 Emory University C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication

Also Published As

Publication number Publication date
CA2929539A1 (en) 2015-05-14
EA201690937A1 (ru) 2017-02-28
SG11201603469UA (en) 2016-05-30
KR20160068981A (ko) 2016-06-15
IL245511A0 (en) 2016-06-30
AR099283A1 (es) 2016-07-13
EP3065778A1 (en) 2016-09-14
JP2016540041A (ja) 2016-12-22
PH12016500824A1 (en) 2016-06-13
WO2015069711A1 (en) 2015-05-14
AU2014346877A1 (en) 2016-05-26
CN105873611A (zh) 2016-08-17
US20160289188A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2018003472A (es) Moduladores de la expresion de kras.
MX2017013562A (es) Reguladores de microbioma y usos relacionados de los mismos.
GEP20247593B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
MX2020011749A (es) Composiciones y metodos para modular la expresion de pkk.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2021008281A (es) Estimuladores de guanilato ciclasa soluble (sgc).
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
WO2015073587A3 (en) Synthetic membrane-receiver complexes
IN2015DN01156A (es)
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
MX2016002075A (es) Inhibidores de indolamina 2,3-dioxigenasa (ido).
NZ755605A (en) Compositions for modulating tau expression
MX2018008105A (es) Compuestos inhibidores de metaloenzima.
PH12015502161A1 (en) Therapeutic compounds and compositions
IN2015DN00438A (es)
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
MX2015001250A (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
EA201591278A1 (ru) Композиции, содержащие c1-inh, и способы профилактики и лечения расстройств, ассоциированых с дефицитом ингибитора с1 эстеразы
IN2014DN06792A (es)
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
TW201713333A (en) Methods of treating a neurodegenerative disease
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP3328864A4 (en) COMPOUNDS AND THERAPEUTIC COMPOSITIONS FOR THE TREATMENT OF SOCIAL DISORDERS AND ADDICTION-RELATED DISORDERS
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same